Hsbc Holdings PLC Decreases Stock Holdings in Insmed, Inc. $INSM

Hsbc Holdings PLC lowered its position in shares of Insmed, Inc. (NASDAQ:INSM) by 5.5% in the first quarter, HoldingsChannel.com reports. The firm owned 116,456 shares of the biopharmaceutical company’s stock after selling 6,811 shares during the quarter. Hsbc Holdings PLC’s holdings in Insmed were worth $19,038,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after buying an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. boosted its position in shares of Insmed by 2.3% during the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after acquiring an additional 475,832 shares in the last quarter. State Street Corp increased its holdings in shares of Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after acquiring an additional 1,217,390 shares during the last quarter. RTW Investments LP increased its holdings in shares of Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after acquiring an additional 1,758,321 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Insmed by 14.4% in the 4th quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after acquiring an additional 539,625 shares during the last quarter.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 21,398 shares of Insmed stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the transaction, the chief executive officer owned 258,917 shares of the company’s stock, valued at $26,751,304.44. The trade was a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 54,590 shares of company stock worth $5,793,738. 2.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on INSM. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, June 10th. Mizuho set a $192.00 price target on Insmed in a report on Tuesday, June 16th. BMO Capital Markets assumed coverage on shares of Insmed in a research note on Monday. They issued an “outperform” rating and a $192.00 price target on the stock. Leerink Partners raised their price objective on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. Finally, Royal Bank Of Canada reduced their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $209.13.

Insmed Stock Performance

Shares of INSM stock opened at $108.62 on Wednesday. The stock’s 50-day moving average is $105.64 and its two-hundred day moving average is $134.69. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The firm has a market cap of $23.54 billion, a price-to-earnings ratio of -18.89 and a beta of 0.78.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period in the previous year, the business earned ($1.42) EPS. Analysts predict that Insmed, Inc. will post -2.43 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.